BeiGene Reports H1 Net Profit of $464 Million, Up 385.8% YoY
Nashnova编辑部
BeiGene's first-half net profit hit $464 million, nearly quadrupling year-on-year, as its flagship cancer drug zanubrutinib crossed $1.2 billion in single-quarter revenue — a milestone marking the Chinese biotech's shift from cash-burn mode to scaled profitability.
Profit nearly quadrupled — where did the money come from?
H1 total revenue reached $3.219 billion, up 32.3% year-on-year; GAAP net income was $464 million, up 385.8%.
This means → revenue grew by a third while profit nearly quadrupled, a clear sign that scale economics are kicking in — each incremental dollar of sales now drops far more to the bottom line.
Non-GAAP net income came in at $820 million, with diluted ADS earnings of $3.84 — roughly double the GAAP figure of $2.05, the gap driven mainly by non-cash items such as share-based compensation.
Why can one drug carry the entire result?
Zanubrutinib (BRUKINSA®) — a BTK inhibitor, an oral cancer drug targeting blood cancers — delivered $1.2 billion in Q2 revenue alone, up 31% year-on-year.
In plain terms = one drug, one quarter, $1.2 billion — that is "blockbuster" territory in the global oncology market.
The U.S. and Europe drove most of the incremental growth. Zanubrutinib's penetration in Western markets is still climbing, meaning the gains are not a China-domestic story.
Is there enough cash to keep expanding?
Cash and equivalents stood at $5.1 billion as of June 30; H1 free cash flow reached $596 million, with operating cash flow staying positive.
This means → the company is not just profitable — it is retaining the cash it earns, with no need to raise external capital.
Management flagged "prudent and strategic capital deployment" and active pursuit of partnerships. $5.1 billion in cash gives it real bargaining power at the table.
What should investors watch in H2?
BeiGene expects product revenue to "grow significantly" in H2 and beyond, but delivery hinges on one key variable: whether zanubrutinib's penetration in the U.S. and Europe can keep rising.
In plain terms = the drug has proven it can sell; the question is how many more physicians will prescribe it and how many new markets it can crack.
Tislelizumab (a PD-1 immunotherapy) and XGEVA® (licensed from Amgen for bone tumors) also contribute revenue, but at far smaller scale — single-product dependence remains a structural risk worth watching.
市场有风险，内容仅供研究参考，不构成投资建议。